Base de dados : MEDLINE
Pesquisa : E02.642.249 [Categoria DeCS]
Referências encontradas : 8630 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 863 ir para página                         

  1 / 8630 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28459931
[Au] Autor:Trepanowski JF; Kroeger CM; Barnosky A; Klempel MC; Bhutani S; Hoddy KK; Gabel K; Freels S; Rigdon J; Rood J; Ravussin E; Varady KA
[Ad] Endereço:Department of Kinesiology and Nutrition, University of Illinois at Chicago.
[Ti] Título:Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial.
[So] Source:JAMA Intern Med;177(7):930-938, 2017 Jul 01.
[Is] ISSN:2168-6114
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Alternate-day fasting has become increasingly popular, yet, to date, no long-term randomized clinical trials have evaluated its efficacy. Objective: To compare the effects of alternate-day fasting vs daily calorie restriction on weight loss, weight maintenance, and risk indicators for cardiovascular disease. Design, Setting, and Participants: A single-center randomized clinical trial of obese adults (18 to 64 years of age; mean body mass index, 34) was conducted between October 1, 2011, and January 15, 2015, at an academic institution in Chicago, Illinois. Interventions: Participants were randomized to 1 of 3 groups for 1 year: alternate-day fasting (25% of energy needs on fast days; 125% of energy needs on alternating "feast days"), calorie restriction (75% of energy needs every day), or a no-intervention control. The trial involved a 6-month weight-loss phase followed by a 6-month weight-maintenance phase. Main Outcomes and Measures: The primary outcome was change in body weight. Secondary outcomes were adherence to the dietary intervention and risk indicators for cardiovascular disease. Results: Among the 100 participants (86 women and 14 men; mean [SD] age, 44 [11] years), the dropout rate was highest in the alternate-day fasting group (13 of 34 [38%]), vs the daily calorie restriction group (10 of 35 [29%]) and control group (8 of 31 [26%]). Mean weight loss was similar for participants in the alternate-day fasting group and those in the daily calorie restriction group at month 6 (-6.8% [95% CI, -9.1% to -4.5%] vs -6.8% [95% CI, -9.1% to -4.6%]) and month 12 (-6.0% [95% CI, -8.5% to -3.6%] vs -5.3% [95% CI, -7.6% to -3.0%]) relative to those in the control group. Participants in the alternate-day fasting group ate more than prescribed on fast days, and less than prescribed on feast days, while those in the daily calorie restriction group generally met their prescribed energy goals. There were no significant differences between the intervention groups in blood pressure, heart rate, triglycerides, fasting glucose, fasting insulin, insulin resistance, C-reactive protein, or homocysteine concentrations at month 6 or 12. Mean high-density lipoprotein cholesterol levels at month 6 significantly increased among the participants in the alternate-day fasting group (6.2 mg/dL [95% CI, 0.1-12.4 mg/dL]), but not at month 12 (1.0 mg/dL [95% CI, -5.9 to 7.8 mg/dL]), relative to those in the daily calorie restriction group. Mean low-density lipoprotein cholesterol levels were significantly elevated by month 12 among the participants in the alternate-day fasting group (11.5 mg/dL [95% CI, 1.9-21.1 mg/dL]) compared with those in the daily calorie restriction group. Conclusions and Relevance: Alternate-day fasting did not produce superior adherence, weight loss, weight maintenance, or cardioprotection vs daily calorie restriction. Trial Registration: clinicaltrials.gov Identifier: NCT00960505.
[Mh] Termos MeSH primário: Restrição Calórica/métodos
Doenças Cardiovasculares/prevenção & controle
Jejum
Obesidade
[Mh] Termos MeSH secundário: Adulto
Glicemia/análise
Glicemia/metabolismo
Doenças Cardiovasculares/metabolismo
Dietoterapia/métodos
Jejum/fisiologia
Jejum/psicologia
Comportamento Alimentar/fisiologia
Feminino
Seres Humanos
Insulina/análise
Insulina/sangue
Masculino
Meia-Idade
Obesidade/diagnóstico
Obesidade/dietoterapia
Obesidade/metabolismo
Obesidade/psicologia
Avaliação de Processos e Resultados (Cuidados de Saúde)
Cooperação do Paciente
Fatores de Risco
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Insulin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jamainternmed.2017.0936


  2 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368827
[Au] Autor:Akbar SR; Ahmed US; Iqbal HI
[Ti] Título:Review of Hyperkalemia in End Stage Renal Disease.
[So] Source:W V Med J;112(6):34-8, 2016 Nov-Dec.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Potassium balance is maintained in the body by balancing the intake with the excretion and the transcellular shifts of potassium. Excretion of potassium is mainly renal as the contribution of the colon to the net potassium secretion of the colon to the net potassium secretion is trivial in patients with normal renal function. As the majority of potassium excretion is renal, it is not surprising to note that patients with end stage renal disease (ESRD) are at an increased risk of developing hyperkalemia in ESRD patients has been estimated to be 3-5%. Maintenance of a stable serum potassium level in patients with ESRD is crucial. We will review the various measures for the management and prevention of hyperkalemia in ESRD patients such as dietary restrictions, dialysis and drugs enhancing extra renal elimination of potassium.
[Mh] Termos MeSH primário: Hiperpotassemia/sangue
Hiperpotassemia/terapia
Falência Renal Crônica/sangue
Falência Renal Crônica/terapia
Diálise Renal
[Mh] Termos MeSH secundário: Idoso
Gluconato de Cálcio/uso terapêutico
Complicações do Diabetes/terapia
Dietoterapia/métodos
Emergências
Seres Humanos
Hipoglicemiantes/uso terapêutico
Insulina/uso terapêutico
Masculino
Diálise Renal/métodos
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Insulin); SQE6VB453K (Calcium Gluconate)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  3 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29217800
[Au] Autor:Sachdeva A
[Ad] Endereço:National President, Indian Academy of Pediatrics, 2017 anupamace@yahoo.co.in.
[Ti] Título:Dietary Interventions for Rare Metabolic Disorders - Now Available in India!
[So] Source:Indian Pediatr;54(11):909-910, 2017 11 15.
[Is] ISSN:0974-7559
[Cp] País de publicação:India
[La] Idioma:eng
[Mh] Termos MeSH primário: Erros Inatos do Metabolismo/dietoterapia
[Mh] Termos MeSH secundário: Dietoterapia/métodos
Seres Humanos
Índia
Recém-Nascido
Pediatria/organização & administração
Doenças Raras/dietoterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  4 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390535
[Au] Autor:Gutiérrez-Castrellón P; Indrio F; Bolio-Galvis A; Jiménez-Gutiérrez C; Jimenez-Escobar I; López-Velázquez G
[Ad] Endereço:Center for Translational Research on Early Programming Nutrition and Mother-Child Nutrition, Hospital General Dr Manuel Gea González & Dirección de Investigación. Universidad Tecnológica de México-Unitec México.
[Ti] Título:Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network meta-analysis.
[So] Source:Medicine (Baltimore);96(51):e9375, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: 5% to 40% of infants cry excessively, usually accompanied by fussiness and excessive of gas. There are no uniform criteria for treatment of infantile colic. Lactobacillus reuteri DSM 17938 has been used with promising results. The objective of this network-meta-analysis (NMA) is to compare the efficacy of L reuteri DSM 17938 with other interventions for infantile colic. METHODS: RCTs, published between 1960 and 2015 for the treatment of infantile colic were included. Primary outcome was duration of crying after 21 to 28 days of treatment. Different databases were searched. Information was analyzed using control group as central axis. A random effect model was used. Hedges standard mean difference (SMD) and odds ratio (OR) were calculated. A SUCRA analysis was performed to evaluate superiority for each intervention. RESULTS: 32 RCTs were analyzed, including 2242 patients. Studies with L reuteri DSM 17938 versus Ctrl., Diet versus Ctrl. and Acupuncture versus Ctrl. were the most influential studies in the NMA. L reuteri DSM 17938 [WMD -51.3 h (CI95% -72.2 to -30.5 h), P .0001] and dietetic approaches [WMD -37.4 h (CI95% -56.1 to -18.7 h), P .0001] were superior compared to the other treatments. CONCLUSIONS: L reuteri DSM 17938 and some dietetic approaches are better to other interventions for treatment of infantile colic.
[Mh] Termos MeSH primário: Cólica/terapia
Lactobacillus reuteri
Probióticos/uso terapêutico
[Mh] Termos MeSH secundário: Dietoterapia
Seres Humanos
Lactente
Modelos Estatísticos
Razão de Chances
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009375


  5 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29246363
[Au] Autor:Gidding SS; Bacha F; Bjornstad P; Levitt Katz LE; Levitsky LL; Lynch J; Tryggestad JB; Weinstock RS; El Ghormli L; Lima JAC; TODAY Study Group
[Ad] Endereço:Nemours Cardiac Center, Alfred I. DuPont Hospital for Children, Wilmington, DE.
[Ti] Título:Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study.
[So] Source:J Pediatr;192:86-92.e5, 2018 Jan.
[Is] ISSN:1097-6833
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To examine cardiac biomarkers over time in youth-onset type 2 diabetes, and relate serum concentrations to cardiovascular disease risk factors, and left ventricular structure and function. STUDY DESIGN: TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) was a multicenter randomized trial of 3 treatments including 521 participants with type 2 diabetes, aged 10-17 years, and with 2-6 years of follow-up. Participants were 36% male, obese, and ethnically diverse. Annual serum concentrations of brain natriuretic peptide, troponin, tumor necrosis factor (TNF)-α, receptors 1 and 2 were related to blood pressure, body mass index, hemoglobin A1c, and left ventricular ejection fraction, diastolic function, relative wall thickness, and mass. RESULTS: Elevated concentrations of brain natriuretic peptide (≥100 pg/mL), TNF-α (≥5.6 pg/mL) and troponin (≥0.01 ng/mL), were present in 17.8%, 18.3%, and 34.2% of the cohort, respectively, at baseline, and in 15.4%, 17.1%, and 31.1% at the end of the study, with wide variability over time, without persistence in individuals or clear relationship to glycemia or cardiovascular structure/function. TNF receptors concentrations were increased at baseline and not significantly different from end-of-study concentrations. Adverse echocardiographic measures were more likely in the highest TNF receptor tertile (all P < .05): higher left ventricular mass (39.3 ± 9.0 g/m ), left atrial internal dimension (3.7 ± 0.4 cm) and E/Em ratio, a measure of diastolic dysfunction (6.2 ± 1.9). After adjustment for body mass index, these relationships were no longer significant. CONCLUSIONS: Elevated serum concentrations of cardiac biomarkers were common in youth with type 2 diabetes, but their clinical significance is unclear and will require further long-term study. TRIAL REGISTRATION: ClinicalTrials.govNCT00081328.
[Mh] Termos MeSH primário: Biomarcadores/sangue
Doenças Cardiovasculares/etiologia
Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/terapia
[Mh] Termos MeSH secundário: Adolescente
Doenças Cardiovasculares/sangue
Doenças Cardiovasculares/diagnóstico por imagem
Doenças Cardiovasculares/fisiopatologia
Criança
Terapia Combinada
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/fisiopatologia
Dietoterapia
Quimioterapia Combinada
Ecocardiografia
Terapia por Exercício
Feminino
Seguimentos
Ventrículos do Coração/diagnóstico por imagem
Ventrículos do Coração/fisiopatologia
Seres Humanos
Hipoglicemiantes/uso terapêutico
Masculino
Metformina/uso terapêutico
Fatores de Risco
Tiazolidinedionas/uso terapêutico
Resultado do Tratamento
Função Ventricular Esquerda
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hypoglycemic Agents); 0 (Thiazolidinediones); 05V02F2KDG (rosiglitazone); 9100L32L2N (Metformin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  6 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27777128
[Au] Autor:Stark LJ; Filigno SS; Bolling C; Ratcliff MB; Kichler JC; Robson SL; Simon SL; McCullough MB; Clifford LM; Stough CO; Zion C; Ittenbach RF
[Ad] Endereço:Department of Pediatrics, Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, United States. Electronic address: Lori.Stark@cchmc.org.
[Ti] Título:Learning about Activity and Understanding Nutrition for Child Health (LAUNCH): Rationale, design, and implementation of a randomized clinical trial of a family-based pediatric weight management program for preschoolers.
[So] Source:Contemp Clin Trials;52:10-19, 2017 01.
[Is] ISSN:1559-2030
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity affects nearly 2 million preschool age children in the United States and is not abating. However, research on interventions for already obese preschoolers is limited. To address this significant gap in the literature, we developed an intervention targeting obesity reduction in 2 to 5year olds, Learning about Activity and Understanding Nutrition for Child Health (LAUNCH). This paper describes the rationale, design, participant enrollment, and implementation of a 3-arm randomized, parallel-group clinical trial comparing LAUNCH to a motivational-interviewing intervention (MI) and standard care (STC), respectively. Whereas LAUNCH was designed as a skills based intervention, MI focused on addressing the guardian's motivation to make changes in diet and activity and providing tools to do so at the guardian's level of readiness to implement changes. Child body mass index z-score was the primary outcome, assessed at pretreatment, posttreatment (Month 6), and 6 and 12month follow-ups (Months 12 and 18). Mechanisms of weight change (e.g., dietary intake, physical activity) and environmental factors associated with weight (e.g., foods available in the home, caregiver diet) were also assessed. This study is unique because it is one of the few randomized controlled trials to examine a developmentally informed, clinic and home skills based behavioral family intervention for preschoolers who are already obese. Being obese during the preschool years increases the likelihood of remaining obese as an adult and is associated with serious health conditions; if this intervention is successful, it has the potential to change the health trajectories for young children with obesity.
[Mh] Termos MeSH primário: Dietoterapia
Exercício
Família
Obesidade Pediátrica/terapia
[Mh] Termos MeSH secundário: Pré-Escolar
Comportamento Alimentar
Feminino
Seres Humanos
Masculino
Entrevista Motivacional
Pais
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  7 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240374
[Au] Autor:Goldfarb DS; Grasso M
[Ti] Título:Case Study - Case Studies in Cystinuria.
[So] Source:Urol Nurs;37(2):90-3, 2017 Mar-Apr.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The diagnosis and treatment of patients with rare inherited metabolic disorders associated with recurrent and often obstructive kidney stones are important to the prevention of chronic kidney disease or end stage renal disease. Two case studies in this article describe the diagnosis and management of cystinuria, the most common rare kidney stone disorder.
[Mh] Termos MeSH primário: Cistinúria/diagnóstico
Íleo/transplante
Cálculos Renais/cirurgia
Ureter/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Cistinúria/complicações
Cistinúria/terapia
Dietoterapia
Diuréticos/uso terapêutico
Feminino
Hidratação
Seres Humanos
Cálculos Renais/etiologia
Masculino
Adesão à Medicação
Citrato de Potássio/uso terapêutico
Procedimentos Cirúrgicos Reconstrutivos
Insuficiência Renal Crônica/etiologia
Bicarbonato de Sódio
Tiopronina/uso terapêutico
Tomografia Computadorizada por Raios X
Ureteroscopia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diuretics); 8MDF5V39QO (Sodium Bicarbonate); C5W04GO61S (Tiopronin); EE90ONI6FF (Potassium Citrate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  8 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28741385
[Au] Autor:Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
[Ad] Endereço:a Department of Diabetes and Metabolic Diseases, Graduate School of Medicine , The University of Tokyo , Tokyo , Japan.
[Ti] Título:Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
[So] Source:Expert Opin Pharmacother;18(13):1291-1300, 2017 Sep.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the efficacy and safety of teneligliptin as add-on to insulin monotherapy in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: In a 16-week, double-blind period, 148 Japanese T2DM patients with inadequate glycemic control with insulin and diet/exercise therapies were randomized to placebo or teneligliptin 20 mg. In a subsequent 36-week, open-label period, all patients received teneligliptin once daily. The primary outcome measure was change in HbA1c at the end of the double-blind period. RESULTS: The difference between placebo and teneligliptin in change in HbA1c in the double-blind period (least squares mean ± SE) was -0.80% ± 0.11%; teneligliptin was superior (ANCOVA, P < 0.001). The HbA1c-lowering effect of teneligliptin was maintained throughout the open-label period. The incidence of adverse events was 53.5% with placebo and 44.2% with teneligliptin in the double-blind period, 66.7% in the placebo/teneligliptin group in the open-label period, and 77.9% in the teneligliptin/teneligliptin group over both double-blind/open-label periods. The incidence of hypoglycemic symptoms was 11.1% in the placebo/teneligliptin group in the open-label period and 27.3% in the teneligliptin/teneligliptin group over both double-blind/open-label periods. CONCLUSION: Teneligliptin was effective and well tolerated in Japanese T2DM patients with inadequate glycemic control. CLINICAL TRIAL REGISTRATION: NCT02081599.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Hipoglicemiantes/uso terapêutico
Insulina/uso terapêutico
Pirazóis/uso terapêutico
Tiazolidinas/uso terapêutico
[Mh] Termos MeSH secundário: Glicemia/efeitos dos fármacos
Terapia Combinada
Dietoterapia
Método Duplo-Cego
Quimioterapia Combinada
Terapia por Exercício
Feminino
Hemoglobina A Glicada/análise
Seres Humanos
Hipoglicemiantes/administração & dosagem
Hipoglicemiantes/efeitos adversos
Insulina/administração & dosagem
Insulina/efeitos adversos
Japão
Masculino
Meia-Idade
Pirazóis/administração & dosagem
Pirazóis/efeitos adversos
Tiazolidinas/administração & dosagem
Tiazolidinas/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine); 0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 0 (Insulin); 0 (Pyrazoles); 0 (Thiazolidines)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180124
[Lr] Data última revisão:
180124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1359259


  9 / 8630 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28991935
[Au] Autor:Saunders KH; Shukla AP; Igel LI; Aronne LJ
[Ad] Endereço:Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Cornell Medicine, New York, NY, USA. Email: kph2001@med.cornell.edu.
[Ti] Título:Obesity: When to consider medication.
[So] Source:J Fam Pract;66(10):608-616, 2017 Oct.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:These 4 cases illustrate how weight loss drugs--including the 4 newest--can be integrated into a treatment plan that includes diet, exercise, and behavior modification.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/uso terapêutico
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Terapia Comportamental
Terapia Combinada
Dietoterapia
Terapia por Exercício
Feminino
Seres Humanos
Masculino
Meia-Idade
Obesidade/terapia
Programas de Redução de Peso
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Obesity Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE


  10 / 8630 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28941533
[Au] Autor:Heidemann SM; Nair A; Bulut Y; Sapru A
[Ad] Endereço:Department of Pediatrics, Wayne State University, Detroit, MI 48202, USA.
[Ti] Título:Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children.
[So] Source:Pediatr Clin North Am;64(5):1017-1037, 2017 Oct.
[Is] ISSN:1557-8240
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acute respiratory distress syndrome (ARDS) is a syndrome of noncardiogenic pulmonary edema and hypoxia that accompanies up to 30% of deaths in pediatric intensive care units. Pediatric ARDS (PARDS) is diagnosed by the presence of hypoxia, defined by oxygenation index or Pao /Fio ratio cutoffs, and new chest infiltrate occurring within 7 days of a known insult. Hallmarks of ARDS include hypoxemia and decreased lung compliance, increased work of breathing, and impaired gas exchange. Mortality is often accompanied by multiple organ failure. Although many modalities to treat PARDS have been investigated, supportive therapies and lung protective ventilator support remain the mainstay.
[Mh] Termos MeSH primário: Cuidados Críticos/métodos
Insuficiência Respiratória/fisiopatologia
Insuficiência Respiratória/terapia
[Mh] Termos MeSH secundário: Doença Aguda
Criança
Terapia Combinada
Dietoterapia
Circulação Extracorpórea
Hidratação/métodos
Seres Humanos
Respiração Artificial/efeitos adversos
Respiração Artificial/métodos
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170925
[St] Status:MEDLINE



página 1 de 863 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde